Inspire Investing LLC Has $352,000 Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Inspire Investing LLC boosted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 19.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,073 shares of the life sciences company’s stock after buying an additional 1,930 shares during the period. Inspire Investing LLC’s holdings in Integra LifeSciences were worth $352,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Blue Trust Inc. raised its stake in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC lifted its stake in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the period. Valley National Advisers Inc. acquired a new stake in Integra LifeSciences during the first quarter worth about $63,000. Allspring Global Investments Holdings LLC grew its position in Integra LifeSciences by 58.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after buying an additional 1,711 shares in the last quarter. Finally, Northwest Investment Counselors LLC bought a new position in Integra LifeSciences during the first quarter valued at about $143,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $17.40 on Monday. The firm has a market cap of $1.37 billion, a PE ratio of 34.80, a price-to-earnings-growth ratio of 0.60 and a beta of 1.10. The company’s 50-day moving average price is $22.69 and its two-hundred day moving average price is $27.79. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a 12 month low of $16.96 and a 12 month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same period in the prior year, the company earned $0.71 EPS. Integra LifeSciences’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Truist Financial decreased their price objective on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. Citigroup dropped their price objective on shares of Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating for the company in a research note on Thursday, August 22nd. BTIG Research decreased their target price on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a research report on Wednesday, August 28th. JMP Securities lowered their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Finally, Morgan Stanley lifted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.